Mechanistically, sorafenib-related antiangiogenic therapy-induced hypoxia-activated HIF-1α/NF-κB signaling increases chemokine CXCL5 secretion in HCC cells, thereby recruiting TAN and inhibiting apoptosis. Here, HIF1A is linked to hepatocellular carcinoma.